奥沙利铂联合替吉奥治疗晚期结直肠癌的临床效果

目的探讨采取奥沙利铂联合替吉奥治疗晚期结直肠癌的临床疗效。方法选取2016年5月～2017年5月期间我院接收的68例晚期结直肠癌患者,将入选者随机分为对照组(n=34,采取奥沙利铂+卡培他滨治疗)与观察组(n=34,采取奥沙利铂联合替吉奥治疗),两组共治疗2个疗程,观察疗效及1年生存率、不良反应发生率等。结果治疗后,观察组患者的客观缓解率明显高于对照组(P0.05);观察组患者1年生存率为70.59%(24/34),对照组为52.94%(18/34),两组比较差异显著(P0.05)。观察组中位疾病进展时间为(8.22±0.52)个月,对照组为(8.11±0.43)个月(P0.05);观察组血小板减少、呕心呕吐、贫血、中性粒细胞减少率较对照组明显要低(P0.05)。结论奥沙利铂联合替吉奥相比于奥沙利铂联合卡培他滨方案,对晚期结直肠癌的临床疗效更为显著,安全性更高,值得推广。

Clinical effect of oxaliplatin combined with tegafur in the treatment of advanced colorectal cancer

Objective To investigate the clinical efficacy of oxaliplatin combined with tegafur in the treatment of advanced colorectal cancer.Methods 68 patients with advanced rectal cancer in our hospital from May 2016 to May 2017 were enrolled.The patients were randomly divided into the control group(n=34,treated with oxaliplatin+capecitabine)and the observation group(n=34,treated with oxaliplatin combined with tegafur).The two groups were treated for 2 courses.The efficacy,1-year survival rate,adverse reaction rate and so on were observed.Results After treatment,the objective response rate of the observation group was significantly higher than that of the control group(P<0.05).The 1-year survival rate of the observation group was 70.59%(24/34),and that of the control group was 52.94%(18/34).The difference between the two groups was significant(P<0.05).The median disease progression time was(8.22±0.52)months in the observation group and(8.11±0.43)months in the control group(P>0.05).The incidences of thrombocytopenia,vomiting and vomiting,anaemia and neutropenia in the observation group were significantly higher than those in the control group(P<0.05).Conclusion Oxaliplatin combined with tegafur is more effective than oxaliplatin combined with capecitabine in the treatment of advanced colorectal cancer,and is more safe and worth promoting.